LifeVantage Co. (NASDAQ:LFVN – Get Free Report) fell 1% during mid-day trading on Thursday . The stock traded as low as $14.51 and last traded at $15.10. 42,697 shares were traded during trading, a decline of 33% from the average session volume of 63,692 shares. The stock had previously closed at $15.25.
LifeVantage Trading Up 6.2 %
The company has a market cap of $200.82 million, a price-to-earnings ratio of 50.13 and a beta of 0.87. The stock’s fifty day simple moving average is $13.42 and its 200 day simple moving average is $9.94.
LifeVantage (NASDAQ:LFVN – Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The company had revenue of $47.21 million for the quarter. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%.
LifeVantage Dividend Announcement
Hedge Funds Weigh In On LifeVantage
Large investors have recently made changes to their positions in the stock. Ritholtz Wealth Management raised its position in LifeVantage by 62.0% in the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after purchasing an additional 10,974 shares during the period. Barclays PLC grew its stake in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after buying an additional 11,608 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of LifeVantage by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 475,021 shares of the company’s stock valued at $2,874,000 after buying an additional 12,809 shares during the period. Hantz Financial Services Inc. acquired a new position in LifeVantage during the 2nd quarter worth about $91,000. Finally, Renaissance Technologies LLC boosted its holdings in LifeVantage by 2.1% during the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after acquiring an additional 17,300 shares during the period. 35.32% of the stock is currently owned by institutional investors and hedge funds.
LifeVantage Company Profile
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Featured Articles
- Five stocks we like better than LifeVantage
- The How and Why of Investing in Gold Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Choose Top Rated Stocks
- Texas Instruments: The Old-School Tech Titan Still Delivering
- How Technical Indicators Can Help You Find Oversold StocksĀ
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.